Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia

Xi Jiang1,2,3, Chao Hu1,2,4, Kyle Ferchen1, Ji Nie5, Xiaolong Cui5, Chih-Hong Chen6, Liting Cheng7, Zhixiang Zuo1,8, William Seibel9, Chunjiang He10, Yixuan Tang7, Jennifer R. Skibbe1, Mark Wunderlich11, William C. Reinhold12, Lei Dong1,3, Chao Shen1,3, Stephen Arnowitz2, Bryan Ulrich2, Jiuwei Lu1, Hengyou Weng1,2,3, Rui Su1,3, Huilin Huang1,3, Yungui Wang1,2,4, Chenying Li1,3,4, Xi Qin1,3, James C. Mulloy11, Yi Zheng11, Jiajie Diao1, Jie Jin4, Chong Li7, Paul P. Liu13, Chuan He5, Yuan Chen6 & Jianjun Chen1,2,3

Effective therapy of acute myeloid leukemia (AML) remains an unmet need. DNA methylcytosine dioxygenase Ten-eleven translocation 1 (TET1) is a critical oncoprotein in AML. Through a series of data analysis and drug screening, we identified two compounds (i.e., NSC-311068 and NSC-370284) that selectively suppress TET1 transcription and 5-hydroxymethylcytosine (5hmC) modification, and effectively inhibit cell viability in AML with high expression of TET1 (i.e., TET1-high AML), including AML carrying t(11q23)/MLL-rearrangements and t(8;21) AML. NSC-311068 and especially NSC-370284 significantly repressed TET1-high AML progression in vivo. UC-514321, a structural analog of NSC-370284, exhibited a more potent therapeutic effect and prolonged the median survival of TET1-high AML mice over three fold. NSC-370284 and UC-514321 both directly target STAT3/5, transcriptional activators of TET1, and thus repress TET1 expression. They also exhibit strong synergistic effects with standard chemotherapy. Our results highlight the therapeutic potential of targeting the STAT/TET1 axis by selective inhibitors in AML treatment.
Acute myeloid leukemia (AML) is one of the most common and fatal forms of hematopoietic malignancies. Despite the risk stratifications and treatment-adapted strategies, with standard chemotherapies, only 35–40% of younger (aged <60) and 5–15% of older (aged ≥60) patients with AML can survive over 5 years. Many AML subtypes, such as the MLL-rearranged AMLs, are often associated with unfavorable outcome. Furthermore, current treatment frequently involves intensive post-remission treatment with multiple cycles of high-dose cytarabine (Ara-C), which impairs the quality of life of the patients. While the incidence of AML is continually rising due to aging, most elderly patients cannot bear intensive chemotherapy and are associated with very poor survival. Thus, improved therapeutic strategies with less intensive treatment but a higher cure rate are urgently needed.

The Ten-eleven translocation (TET) proteins (including TET1/2/3) are known to be able to convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), leading to DNA demethylation. TET1, the founding member of the TET family, was first identified as a fusion partner of the MLL gene associated with t(10;11)(q22;q23) in AMI. In contrast to the repression and tumor-suppressor role of TET2 observed in hematopoietic malignancies, we recently showed that TET1 was significantly upregulated in MLL-rearranged AML and played an essential oncogenic role in the development of MLL-fusion-induced leukemia. An independent study by Zhao et al. confirmed the essential oncogenic role of TET1 in the development of myeloid malignancies. Thus, given the fact that knockout of TET1 expression shows only very minor effects on normal development including hematopoiesis, TET1 is an attractive therapeutic target for AML.

In the present study, through a series of in vitro drug screening and in vivo preclinical animal model studies, we identified chemical compounds NSC-370284 and UC-514321 (a more effective analog of NSC-370284) as potent inhibitors that significantly and selectively suppress the viability of AML cells with high level of TET1 expression (i.e., TET1-high AML cells), and dramatically repress the progression of TET1-high AML in mice. These compounds directly bind STAT3/5 as STAT inhibitors and thereby suppress TET1 transcription and TET1 signaling, leading to potent anti-leukemic effects.

Results

NSC-311068 and 370284 inhibit TET1-high AML cell viability. We previously reported the high expression and oncogenic role of TET1 in AML. In fact, high expression of TET1 was found not only in AML, but also in various tumors including uterine cancer, glioma, etc., and especially, in testicular germ cell malignancies (Supplementary Fig. 1). This indicates potential oncogenic role of TET1 in many cancers where TET1 expression is relatively high. In order to identify chemical compounds that may target TET1 signaling, we searched the drug-sensitivity/gene expression database of a total of 20,602 chemical compounds in the NCI-60 collection of cancer cell samples. We found the expression levels of endogenous TET1 showed a significant positive correlation with the responsiveness of cancer cells across the NCI-60 panel to 953 compounds (r > 0.2; P < 0.05). We selected the top 120 with the highest r values and tested their effects on cell viability of a TET1-high AML cell line, i.e., MONOMAC-6/6(9;11). Then, the top 20 showing the most significant inhibitory effects (Supplementary Tables 1–2) were further tested in three other TET1-high AML cell lines including THP-1/1(9;11), KOCL-48/t(4;11), and KASUMI-1/t(8;21) AML cells, along with MONOMAC-6 cells as a positive control (Supplementary Fig. 2a–e and Supplementary Table 3). Actually, we found that TET1 is highly expressed not only in MLL-rearranged AML as we reported previously, but also in AML carrying t(8;21); moreover, depletion of TET1 expression also significantly inhibited t(8;21) fusion gene-induced colony-forming/replating capacity of mouse bone marrow (BM) progenitor cells (Supplementary Fig. 3). Our results showed that NSC-311068 (6-(1-Pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl)-1,3-benzodioxol-5-ol; C_{12}H_{13}N_{2}O_{3} ) and NSC-370284 (Pyrimidine, 4-[[2,4-dinitrophenyl]thio]-; C_{18}H_{11}N_{2}O_{5}S) exhibited the most significant effects in inhibiting cell viability of all four TET1-high AML cell lines, whereas showing no significant inhibition on viability of NB4/t(15;17) AML cells, a control cell line with very low level of TET1 expression (Fig. 1a, b). In the NCI-60 collection, cell lines with relatively higher TET1 expression levels showed more obvious positive correlation between TET1 expression level and activity of both NSC-311068 and NSC-370284, compared to that across the entire NCI-60 panel, whereas cell lines with relatively lower TET1 expression levels exhibited no obvious positive correlation (NSC-311068) or even negative correlation (NSC-370284) (Supplementary Table 2c, d). In TET1-high AML cells, NSC-311068 and NSC-370284 significantly repressed the level of TET1 expression (Fig. 1c), as well as the global 5hmC level (Fig. 1d). In order to rule out the possibility of non-specific toxicity, we reduced the dose of NSC-311068 and NSC-370284 to 25 nM, and tested gene expression and cell viability 24 h after treatment. The low dose, short-term treatments again resulted in a significant downregulation of TET1 transcription, accompanied with a very minor decrease in the viability of MONOMAC-6, THP-1, and KOCL-48 cells (Fig. 1e, f). Thus, it is unlikely that the inhibitory effects of NSC-311068 and NSC-370284 on TET1 expression were due to nonspecific toxicity.

NSC-311068 and 370284 suppress AML progression in vivo. The potential in vivo therapeutic effects of NSC-311068 and 370284 were then tested with the MLL-AF9 AML model. NSC-311068 and especially 370284 treatments significantly inhibited MLL-AF9-induced AML in secondary bone marrow transplantation (BMT) recipient mice, by prolonging the median survival from 49 days (control) to 94 (NSC-311068) or >200 (NSC-370284) days (Fig. 2a). Notably, 57% (4 out of 7) of the NSC-370284-treated mice were cured, as the pathological morphologies in peripheral blood (PB), BM, spleen, and liver tissues all turned to normal (Fig. 2b). The in vivo downregulation of TET1 expression by the compounds at both RNA and protein levels was validated by qPCR (Fig. 2c) and western blotting (Fig. 2d; Supplementary Fig. 13a, b), respectively. In another AML model induced by AML-ETO9a (AE9a), NSC-311068 and NSC-370284 also exhibited remarkable therapeutic effects, with an elongated median survival from 46 days (control) to 95 (NSC-311068) and 122 (NSC-370284) days, respectively (Fig. 2e). Interestingly, NSC-370284 has been reported previously as an analog of the natural product podophyllotoxin (PPT) that was associated with anti-leukemic activity. Given the better therapeutic effect of NSC-370284 in vivo (Fig. 2a, b, e), we decided to focus on NSC-370284 for further studies.

NSC-370284 targets STAT3/5 and suppresses TET1 expression. To decipher the molecular mechanism by which NSC-370284 represses TET1 expression, we adapted the strategy developed by Kapoor and colleagues to identify direct target protein(s) of NSC-370284. Briefly, multiple-drug-resistant clones were established and transcriptome sequencing was conducted to find mutations in each clone; the assumption was that the critical components of the signaling of the drug target(s) would have a high chance to carry mutations in drug-resistant clones. To this...
end, we treated THP-1 AML cells with high to moderate concentration of NSC-370284 for over 100 days and then isolated a set of individual drug-resistant THP-1 single clones (see the representitives in Supplementary Fig. 4a). These drug-resistant cells showed no significant downregulation of TET1 expression upon treatment of NSC-370284 (Supplementary Fig. 4b).

Through RNA-seq of 6 of the NSC-370284-resistant clones, recurrent mutations were found in 14 genes in at least two individual clones. Ingenuity pathway analysis (IPA) was used to analyze biological relationships amongst the 14 mutated genes (Supplementary Table 4). The top five networks identified by IPA, based on Fisher’s exact test, are associated with cancer, hematological disease, immunological disease, etc. (Supplementary Table 5). The top one network identified by IPA involving all of the 14 genes is closely associated with the JAK/STAT5 pathway (Fig. 3a). A number of these genes have been reported to be associated with the JAK/STAT signaling27–35. It is likely that mutations in such genes may overcome NSC-370284-mediated inhibitory effect on AML cell viability/growth, and thereby confer drug resistance to the AML clones. To test this, we chose JAK1 and MSH3 as two representatives and cloned constructs carrying the JAK1^A893G mutant or the MSH3^V600E mutant that was detected in our drug-resistant THP-1 cells (Supplementary Table 4). As expected, forced expression of either mutant at least partially reversed the inhibitory effect of NSC-370284 on AML cell viability (Supplementary Fig. 4c, d).

We next showed knockdown of STAT3 and/or STAT5 in MONOMAC-6 and THP-1 cells resulted in a downregulation of TET1, but not TET2 or TET3 (Fig. 3b; Supplementary Fig. 4e–h). Through searching the UCSC Genome Browser (https://genome.ucsc.edu/index.html), we found that STAT5 has a putative binding site (ttctcgtaccgttttaca tgtg; the consensus binding motif: tccnnnga; Fig. 3c, Site 4) located within the promoter region of TET1 gene, suggesting TET1 might be a direct target of the STAT proteins. The direct binding of STAT3 and STAT5 on the TET1 loci was further validated in MONOMAC-6 cells through chromatin immunoprecipitation (ChIP)-qPCR assay, and such binding could be disturbed by NSC-370284 treatment (Fig. 3c–g).

In NB4 cells, no significant binding of STAT3 or STAT5 on the TET1 loci was detected (Fig. 3h). JAK1 was known
as the upstream activator of the STAT pathway. To our surprise, we found knockdown of TET1 resulted in a reduction of JAK1 transcription in AML cells (Supplementary Fig. 4i). ChIP-qPCR results showed direct binding of TET1 to the JAK1 promoter (Supplementary Fig. 4j). The above findings suggest JAK/STAT pathway promotes TET1 transcription via direct binding of STAT3/5 to the TET1 promoter, and TET1 also binds to the JAK1 promoter and activates JAK1 transcription. Herein we unveil a feedback loop between JAK1/STAT/TET1 in AML.

Our structural analysis suggested a potential direct binding of NSC-370284 to the conserved DNA-binding domain (DBD) of STAT3 or STAT5 (Fig. 3i). Such binding and the binding sites were identified by use of NMR chemical shift perturbation (CSP). Complex formation with compound NSC-370284 induced extensive CSPs at the isoleucine (Ile) residues of STAT3 at 1:2 of protein:ligand molar ratio (Fig. 3j). The CSPs occurred at residues adjacent to the DNA-binding site (I646) and those at or near DBD (Fig. 3j), indicating that compound NSC-370284 binds to STAT3 at or near DBD. The association between STAT3 and the TET1 Cpg island was further verified with electrophoretic mobility shift assay (EMSA); this association could almost be completely blocked by NSC-370284 (Fig. 3k; Supplementary Fig. 13c). In order to test whether NSC-370284 also inhibits the phosphorylation of STAT3 and STAT5, we treated MONOMAC-6 cells with NSC-370284 for a series of time points. Western blotting shows no significant alterations of the levels of STAT3 and STAT5 phosphorylation (Supplementary Figs. 4k, 13d, e). It is likely NSC-370284 mainly competes against DNA for STAT binding, but not suppresses STAT activation. These results indicate that STAT3 and STAT5 are direct targets of NSC-370284, which can interfere with the binding of STAT3/5 to TET1 promoter region and thereby suppress the transcription of TET1. Similarly, a previous study also reported a compound C48, a structural analog of NSC-370284, can bind directly to the DNA-binding domain of STAT3 protein and lead to apoptosis and inhibition of tumor cell growth. Notably, the inhibitory effects of NSC-370284 on the expression of other STAT5 target genes, such as HIF2α, IL2RA and FRA2, were not as obvious as that on TET1 (Supplementary Fig. 4l). The basal enrichment of STAT5 on the promoter of HIF2α, IL2RA, or FRA2 was very low, as compared with that on the TET1 promoter; and the interruption by NSC-370284 on such association was much less obvious (Supplementary Fig. 4m). The very weak, if any, basal affinity of STAT5 with most of its target genes’ promoters without cytokine stimulation (e.g., IL-2, IL-3, or EPO) has been reported before.

Therefore, our results revealed a very strong enrichment of STAT3/5 on TET1 promoter (Fig. 3e–g, k; Supplementary Fig. 4l, m). Moreover, our results indicate that different from typical STAT inhibitors that target STAT kinase activity, NSC-370284 may exert its function mainly through interfering with the binding of STAT protein to the DNA regions which have relatively higher basal affinity to STATs, like the TET1 promoter, in AML cells.

Enhanced therapeutic efficacy of NSC-370284 analog UC-514321. Based on the structure of the initial lead compound NSC-370284, we searched for structural analogs using BioVia Pipeline Pilot (Version 8.5.0.200) against the University of Cincinnati Compound Library, a collection of approximately 360,000 compounds. The 30 structurally most similar compounds were selected to explore the structure activity relationships (SAR)
(Supplementary Table 6). The majority of these compounds share the core aryl amine hydroxybenzodioxole scaffold with NSC-370284, varying primarily in the amine substituents and in the aryl substituents. Analogs lacking either the amine or hydroxyl were inactive. Results of MTS assays showed that one of the analog compounds, UC-514321, most significantly repressed MONOMAC-6 cell viability (Fig. 4a; Supplementary Fig. 5). UC-514321 showed an enhanced effect in repressing the viability of TET1-high AML (including MONOMAC-6, THP-1, and KASUMI-1) cells, as compared with NSC-370284 and other JAK/STAT inhibitors, e.g. Pacritinib, KW-2449, STAT3/5 inhibitor Stattic, or STAT5 inhibitor sc-355979 (Fig. 4b–d). Similar to NSC-370284, UC-514321 showed no inhibitory effect on the viability of TET1-low AML (i.e., NB4) cells (Fig. 4e). Thus, the anti-tumor effect of UC-514321 is also TET1-signaling dependent. Notably, the STAT3/5 specific inhibitors Stattic and sc-...
Fig. 4 Effects of UC-514321 in treating AMLs. a Structures of NSC-370284 and UC-514321. b–e Effects of NSC-370284, UC-514321, and other JAK/STAT pathway inhibitors, i.e., Pacritinib, KW-2449, Static and sc-355979, on the viability of AML cell lines MONOMAC-6 (b), THP-1 (c), KASUMI1 (d), and NB4 (e). Cells were treated with drugs at indicated doses. Cell viability was detected by MTS 48 h post treatment. Error bar indicates SD of triplicate experiments. f–j Enhanced therapeutic effect of UC-514321, relative to NSC-370284, in treating TET1-high AMLs in vivo. Secondary BMT recipient mice were transplanted with primary leukemic BM cells with MLL-AF9 (f), AML-ETO9a (g), MLL-AF10 (h), or FLT3-ITD/NPM1mut (i). Upon the onset of leukemia, the recipient mice were treated with DMSO (control) (n = 5 or 6), 2.5 mg/kg NSC-370284 (n = 5 or 6), or UC-514321 (n = 5 or 6), i.p., once per day, for 10 days. Kaplan–Meier curves are shown. The P values were determined by log-rank test. j Wright–Giemsa staining of mouse PB and BM, or H&E staining of mouse spleen and liver of MLL-AF9 AML secondary BMT recipients with or without drug treatment.
355979 did not show significant inhibitory effects on the viability of these AML cells, probably because their EC50 values are higher than 500 nM, the maximum concentration we tested. Overall, compared to other JAK and/or STAT inhibitors, UC-514321 is more effective and selective in inhibiting the viability of TET1-high AML cells.

Moreover, compared to the parental compound (NSC-370284), UC-514321 also showed an improved therapeutic effect in AML mouse models in vivo. In MLL-AF9-AML mice, UC-514321 prolonged median survival from 49 days (control) to > 200 days, better than NSC-370284 (Fig. 4f). In the A203a-AML model, the median survival of UC-514321 treated mice was 160 days, much longer than the control (46 days) and NSC-370284 (114 days) treated groups (Fig. 4g). Thus, in both AML animal models, UC-514321 prolonged the median survival over three fold (Fig. 4f, g). Moreover, we tested the therapeutic effects of NSC-370284 and UC-514321 in two other AML models, i.e., MLL-AF10 AML and FLT3-ITD/NPM1mut AML.46 NSC-370284 prolonged median survival of MLL-AF10 leukemic mice from 35 days to >50 days, and that of FLT3-ITD/NPM1mut leukemic mice from 21 days to 34 days. UC-514321 showed an even better therapeutic effect, as it prolonged median survival of both MLL-AF10 and FLT3-ITD/NPM1mut leukemic mice to >50 days (Fig. 4h, i). Notably, UC-514321 treatment cured 66.7% (4 out of 6) of the MLL-AF9 AML mice (Fig. 4f, j), and none of the UC-514321-treated FLT3-ITD/NPM1mut AML recipients developed full-blown AML within 50 days (Fig. 4i).

To determine whether the mechanism underlying UC-514321 function is similar to that of NSC-370284, we performed a series of mechanistic studies. As expected, similar to NSC-370284, UC-514321 significantly repressed expression of TET1, but not TET2 or TET3, along with the downregulation of putative target genes of TET1, e.g., HOXA7, HOXA10, MEIS1, PBX3, FLT314,47 etc., and the upregulation of negative targets, e.g., miR-2346, in MONOMAC-6 cells (Fig. 5a, b). Notably, compared to NSC-370284, UC-514321 exhibited an enhanced effect on the changes in gene expressions (Fig. 5a, b). Both NSC-370284 and UC-514321 significantly reduced global 5hmC levels (Fig. 5c; Supplementary Fig. 13f, g), and their inhibitory effect was further confirmed with genome-wide 5hmC-seq in AML cells. We found both NSC-370284 and UC-514321 treatments resulted in around 75% reduction of 5hmC peak enrichment in the whole genome (Supplementary Fig. 6). Similar to NSC-370284 (Fig. 3j), the largest CSPs induced by UC-514321 treatment were also observed at the residues adjacent to DNA-binding surface (I431) and those near or in DBD (Fig. 5d). In contrast, Statick and sc-355979 target the STAT SH2 domain14,45. Therefore, both NSC-370284 and UC-514321 induce CSP at residues at or adjacent to the DNA-binding surface, and thus they likely interfere with STAT protein’s binding to DNA. And this was further verified with ChIP-qPCR assays. In MONOMAC-6 cells, UC-514321 treatment also resulted in a remarkable repression on the binding of STAT3/5 to TET1 promoter, even more significant than NSC-370284 at the CpG region (Fig. 5e–h).

In wild-type mouse BM progenitor cells transduced with MLL-AF9, treatment with NSC-370284 or UC-514321 resulted in a remarkable repression of cell viability, and no such inhibition was observed in Tet1-deficient counterpart cells (Fig. 5i–l). Other JAK/STAT inhibitors (i.e. Pacritinib, KW-2449, Statick, and sc-355979) showed no significant differences in affecting cell viability between wild-type and Tet1-deficient cells (Fig. 5i, j; Supplementary Fig. 7a–d). Further, in MLL-AF9-transduced BM progenitor cells from conditional Tet1 knockout mice, NSC-370284 and UC-514321 also showed no significant effect in inhibiting the viability of the cells with induced Tet1 deficiency (Fig. 5m; Supplementary Fig. 7e). In addition, we created a pLenti-puro vectored Tet1 construct, and transduced it into THP-1 and MONOMAC-6 cells and showed that ectopic expression of Tet1 sufficiently reversed the inhibitory effects of NSC-370284 and UC-514321 and restored viability of the AML cells (Fig. 5n, o). Taken together with the selective effect of NSC-370284 on TET1-high AML cell lines (Fig. 1b), the above results suggest that the anti-leukemic effects of NSC-370284 and UC-514321 are TET1-signaling dependent.

**Toxicity profiling of NSC-370284 and UC-514321.** Cell viability and apoptosis assays were firstly carried out to assess the effects of NSC-370284 and UC-514321 on normal hematopoietic stem/progenitor cells (HSPCs; herein we used c-Kit+BM cells) in vitro. Remarkably, NSC-370284 or UC-514321 treatment dramatically suppressed the viability of AML cells, but not that of normal HSPCs (Supplementary Fig. 8a). In addition, the compounds significantly increased apoptosis in AML cells, but not in normal HSPCs (Supplementary Fig. 8b). Thus, these two compounds showed no obvious toxicity on normal HSPCs. This is consistent with endogenous Tet1 expression pattern, as AML cells with MLL-AF10 or FLT3-ITD/NPM1mut have relatively higher Tet1 expression levels, as compared with normal HSPCs (Supplementary Fig. 8c). To assess potential toxicity of NSC-370284 and UC-514321 in normal tissues, especially the hematopoietic system, in vivo, we injected NSC-370284 or UC-514321 into normal C57BL/6 mice and assessed potential acute toxicity (24 h) or long-term (200 days) toxicity after 10 succeeding days’ administration of the drug. We assessed body weights, spleen and liver weights, white blood cell (WBC) counts, all peripheral blood lineages, as well as granulocytes (Mac1*Gr1*), monocytes (Mac1*Gr1*) and progenitor (c-Kit*) lineages of BM cells, and observed no evidence of either acute or long-term toxicity (Supplementary Figs. 9,10; Supplementary Table 7). The maximum tolerated dose of NSC-370284 and UC-514321 in mice was 65–85.6 mg/kg (Supplementary Table 8). The LD50 was around 123 mg/kg (Supplementary Table 8). Analysis of the pharmacokinetic (PK) properties of UC-514321 showed that the compound had a half-life of 11.02 h in mouse blood (Supplementary Table 9; Supplementary Fig. 11).

**Synergistic effect with standard chemotherapy.** Long-term treatment with a drug may cause drug resistance in patients, and thus combinatory therapy is often required. To treat AML cells that have gained resistance to our inhibitors, we investigated the effects of a set of first-line AML chemotherapy drugs including daunorubicin (DNR), cytarabine (AraC), all-trans retinoic acid (ATRA), azacytidine (AZA), and decitabine (DAC) on the viability of parental THP-1 cells and three NSC-370284-resistant clones (Fig. 6a; Supplementary Fig. 12a–d). Strikingly, all three drug-resistant clones appeared to be much more sensitive to DNR than the parental control (Fig. 6a). NSC-370284 or UC-514321 works synergistically with DNR on inhibiting the viability of THP-1 and KASUMI-1 cells (Fig. 6b, c). The synergistic effect between NSC-370284 or 514321 and the standard chemotherapy (i.e., the “5+3” regimen48) was further validated in vivo. Even administered at relative low doses, the combinatorial treatment of NSC-370284+DNR/AraC or UC-514321+DNR/AraC showed a better therapeutic effect in curing MLL-AF9 AML, as the combinatorial administrations cured 83.3% (5 out of 6) of the AML mice (Fig. 6d, e). Through analysis of the RNA-seq data of the NSC-370284-resistant clones and parental cells, we showed that several gene clusters are known to be associated with drug response, especially response to topoisomerase II inhibitors such as DNR, are enriched in NSC-370284-resistant cells. These gene clusters include JAK/STAT signaling, G2M checkpoint, and that of NSC-370284 or UC-514321, with or without DNR or AraC.
MYC targets, E2F targets, etc. (Supplementary Table 10a). A potential DNR sensitizing mechanism might be through targeting G2M checkpoint. It was shown that overexpression of CDC25, a key phosphatase of G2M checkpoint control, could significantly sensitize tumor cells to doxorubicin treatment49. Our RNA-seq data showed increased CDC25 levels in NSC-370284-resistant AML clones, relative to the parental cells. Also consistent is the enrichment of G2M checkpoint gene cluster in control samples relative to NSC-370284-treated samples (Supplementary Table 10b). The activation of JAK/STAT pathway might, directly or indirectly, contribute to G2M checkpoint abnormality, as reported previously by others 50,51. Therefore, very likely the
deregulation of G2M checkpoint in NSC-370284-resistant clones at least partially explains why the resistant clones, compared to the parental AML cells, are more sensitive to DNR treatment. Overall, the combination of NSC-370284 or UC-514321 with DNR represents a promising therapeutic strategy that will not only be effective in treating patients with TET1-high AMLs at relative low doses, but also avoid the occurrence of resistance to NSC-370284 or UC-514321.

**Discussion**

While knockout of Tet1 expression shows only very minor effects on normal development including hematopoiesis, our recent studies demonstrated that TET1 plays a critical oncogenic role in AML through promoting expression of oncogenic targets (e.g., HOXA9, MEIS1, PBX3, etc.) and repressing expression of tumor-suppressor targets (e.g., mir-22) (18,19,36). Thus, targeting TET1 signaling is a promising therapeutic strategy to treat TET1-high AMLs. In order to target critical oncogenic proteins with catalytic activity, one of the most popular approaches is to interfere with the catalytic activity of oncogenic proteins, such as FLT3 inhibitor Quizartinib that represses the kinase activity of FLT3 (32), STAT inhibitor Statmic that blocks the dimerization of STAT3 (34), etc. However, as shown in a number of clinical reports, treatments of catalytic activity inhibitors often result in aberrant upregulation of the target oncoproteins or trigger gene mutations, which eventually leads to drug resistance (35,36). The discovery of the bromodomain and extra-terminal (BET) inhibitor JQ1 as an effective strategy to target c-Myc signaling (32,33) suggested an alternative strategy of repressing the TET1 signaling instead of directly targeting the enzymatic activity of TET1. Any drugs that efficiently target the expression, i.e., transcription, translation, or degradation, of the oncogenes or oncogenic proteins could largely avoid drug resistance caused by target oncogene upregulation or constitutively activated gene mutations. Moreover, we reported previously that TET1 can recruit polycomb proteins to the promoter region of the mir-22 gene and suppress the primary transcription of this critical tumor-suppressor microRNA, and such transcriptional suppression is independent from TET1’s enzymatic activity (36). Therefore, instead of seeking inhibitors targeting TET1 enzymatic activity directly that are unable to fully repress the function of TET1, we screened for inhibitors that suppress TET1 expression in this study for treating AML.

Through correlation analysis of cell response to 20,602 chemical compounds and TET1 levels of in the NCI-60 collection of cancer cell samples, we finally narrowed down to two candidate chemical compounds (i.e., NSC-311068 and NSC-370284) that both suppressed AML cell viability and TET1 expression. Importantly, both NSC-311068 and especially NSC-370284 showed remarkable therapeutic effects in curing AML in vivo. UC-514321, a structural analog of NSC-370284, exhibited a more potent anti-leukemic activity in vitro and in vivo than NSC-370284. Mechanistically, our TET1-signaling inhibitors directly target STAT3/5, which are direct upstream regulators of TET1 transcription. Remarkably, compared to currently available JAK/STAT inhibitors (e.g., Pacritinib, KW-2449, Statmic, and sc-355979), our compounds (NSC-370284 and UC-514321) exhibit a much higher selectivity and also a higher efficacy in targeting TET1-high AML, which likely due to the unique property of our TET1-signaling inhibitor as they directly bind to the DBD of STAT3/5, interfere with the binding of STAT3/5 to TET1 promoter region, and thereby repress the transcription of TET1. Moreover, we show that both NSC-370284 and UC-514321 exhibit a synergistic effect with DNR in treating TET1-high AML cells in vitro and in vivo. Notably, NSC-370284-resistant THP-1 AML cells are even more sensitive to DNR than parental THP-1 cells. Taken together, our findings highlight the therapeutic potential of targeting TET1, a key oncogenic epigenetic regulator related to DNA demethylation, in AML. Our data also reveal that STAT3 and STAT5 are direct upstream regulators of TET1, and they are druggable targets to suppress TET1 signaling. Our data suggest that application of small-molecule compounds (e.g., NSC-370284 and UC-514321) that selectively and effectively target the STAT/TET1 signaling, especially in combination with standard chemotherapy agents, represents an effective novel therapeutic strategy for the treatment of TET1-high AML (including MLL-rearranged AML and t(8;21) AML), which accounts for approximately 30% of total AML cases. Moreover, these effective inhibitors can also be employed as tool compounds in both basic and translational research to selectively target the STAT/TET1 signaling axis and suppress 5hmC globally.

**Methods**

**Animal studies.** C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice were purchased from the Jackson Lab (Bar Harbor, ME, USA) or Harlan Laboratories, Inc. (Indianapolis, IN, USA) and maintained in house. Both male and female mice were used for the experiments. All laboratory mice were maintained in the animal facility at University of Cincinnati or University of Chicago. All experiments on mice in our research protocol were approved by Institutional Animal Care and Use Committee (IACUC) of University of Cincinnati or University of Chicago. All methods were performed in accordance with the relevant guidelines and regulations. The maintenance, monitoring, and end-point treatment of mice were conducted as described previously (37,46,48,56,57). Randomisation, allocation concealment, and blind outcome assessment were conducted throughout all the experiments.

**Mouse bone marrow transplantation and drug treatment.** Secondary mouse BMT was carried out as described previously (46,56,57). Upon the onset of leukemia (when mice had an engraftment (CD45.1) of over 20% and/or white blood cell counts higher than 4 × 10^9/L, usually 10 days post transplantation), the recipient mice were injected with DMSO control, 2.5 mg/kg NSC-311068, NSC-370284, or UC-514321, i.p., once per day, for 10 days. For the “+s3” and NSC-370284 or UC-514321 combination treatment experiment, after the onset of AML, the recipient mice were treated with PBS control, or NSC-370284 or UC-514321 alone, i.p., once per day, for 10 days or together with the “+s3” treatment. For the “+s3+”
Fig. 6 Synergistic effect of NSC-370284 or UC-514321 with daunorubicin in treating TET1-high AMLs in vitro and in vivo. a NSC-370284-resistant AML cells are sensitive to DNR. Three of the THP-1 NSC-370284-resistant clones (DRC-1–3) and the parental control were treated with DNR at indicated doses. Cell viability was tested 48 h after the treatments. b, c THP-1 (b), and Kasumi-1 (c), cells were treated with DMSO (Ctrl), 25 nM NSC-370284 (upper panels) or UC-514321 (lower panels), and/or 100 nM DNR. Relative cell viability at 48 h post drug treatment is shown. Error bar indicates SD of triplicate experiments. Synergistic therapy of NSC-370284 or UC-514321 in combination with standard chemotherapy. d Secondary BMT recipient mice were transplanted with primary MLL-AF9 leukemic BM cells. Upon the onset of leukemia, the mice were treated with DMSO (control), “5+3” regimen48 alone (i.e., a daily dose of 50 mg/kg Ara-C for five days along with a daily dose of 3 mg/kg DNR during the first three days of Ara-C treatment), or in combination with 10 days’ NSC-370284 or UC-514321 treatment, 2.5 mg/kg, i.p., once per day. Five to nine mice were included in each group. Kaplan-Meier curves are shown. The P values were determined by log-rank test. e Wright-Giemsa staining of mouse PB and BM, or H&E staining of mouse spleen and liver of MLL-AF9 secondary BMT recipients treated with “5+3” alone, or combinational therapy.
treatment, AraC (Cytarabine, Bedford Laboratories) and DNR (Daunorubicin, Sigma-Aldrich) were reconstituted with PBS, filtered, and stored in aliquots at −20 °C. The “5+3” therapy regimen consists of five consecutive daily doses of 50 mg/kg AraC along with 3 μg/kg DNR daily during the first three days of treatment. Drugs were delivered by tail vein and intraperitoneal injection. Weights were taken daily during treatment and doses were recalculated to ensure the mice received a consistent dose of 50 mg/kg AraC and 3 mg/kg DNR every treatment.

In vivo preclinical pharmacokinetic analysis. PK studies of UC-514321 were performed in C57BL/6 mice (18–22 g). Prior to the study, the mice were fasted for 12 h with free access to water. Animals were housed on a 12-h light/dark cycle at 22–24 °C and 30–50% relative humidity. 15.00 mg/kg UC-514321 was administered through intraperitoneal (i.p.) injection. After dosing, blood samples were collected at indicated time points (15 min, 30 min, 1, 2 h, 4 h, 8 h, 12 d, and 24 h). Samples from three animals were collected at each time point. Approximately 500 μL of blood was collected via orbital vein from each mouse anesthetized with isoflurane. In total, 200 μL blood was then mixed with 600 μL methanol by vortex, spun twice at 11,000 rpm, 4 °C, for 15 min to remove insoluble matter. Supernatant was collected and transferred to 2 mL liquid sample vials. An aliquot of 40 μL mixture solution was injected for LC analysis. Standard curves were prepared in blood covering the concentration range of 50–3,000 ng/mL. Using the data from the standard curves, calibration curves were generated for PK tests. The PK parameters were calculated using a noncompartmental model with PKsolver26,27.

Cell culture and drug treatment. MONOMAC-6, THP-1, KOCI-48, KASM1-1, ML-2, and NB4 cells were purchased from ATCC (Manassas, VA), and cultured as described previously28,29. All cell lines were tested for mycoplasma contamination yearly using a PCR Mycoplasma Test Kit (PromoKine) and were proven to be mycoplasma negative. All cell lines were authenticated through STR profiling yearly.

Cell transfection and retrovirus infection. siRNAs were transfected into MONOMAC-6, THP-1, KOCI-48, KASM1-1, ML-2, and NB4 cells with polybrene in cell culture media containing 10% FBS, using the Amaxa Nucleofector Technology (Ammaxa Biosystems, Berlin, Germany). Experiments were performed 48 h after transfection. Retrovirus infection of mouse BM progenitor cells were conducted as described previously with some modifications30,31. Briefly, retrovirus vectors were co-transfected with PCL-Eco packaging vector (IMGENEX, San Diego, CA) into HEK293 cells using Effectene Transfection Reagent (Qiagen, Valencia, CA) to produce retrovirus. BM cells were harvested from a cohort of 4– to 6-week-old C57BL/6, THP-1, or Cre-Tet39 donor mice after 5 days of 5-fluorouracil (5-FU) treatment, and primary hematopoietic progenitor cells were enriched with Mouse Lineage Cell Depletion Kit (Miltenyi Biotec Inc., Auburn, CA). An aliquot of enriched hematopoietic progenitor cells was added to retroviral supernatant together with polybrene in cell culture plates, which were centrifuged at 2000 × g for 2 h at 32 °C (i.e., “spincoculation”) and then the medium was replaced with fresh media and incubated for 20 h at 37 °C. Next day, the same procedure was repeated once. Infected cells were grown in complete culture media containing 10 ng/mL IL-6, 100 ng/mL murine recombinant SCF (R&D Systems, Minneapolis, MN), along with 1.0 mg/mL of G418. Experiments were performed 7 days after infection.

RNA extraction and quantitative RT-PCR. Total RNA was extracted with the miRNeasy extraction kit (Qiagen) and was used as template for quantitative RT-PCR (qPCR) analysis as described previously19,40,41.

Cell apoptosis and proliferation assays. These experiments were conducted as described previously42,43. With ApoLive-Glo Multiplex Assay Kit, or CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison, WI).

NMR chemical shift perturbation. Specific Ile-methyl labeled STAT3 for NMR studies was prepared as described previously44,45. For each compound, STAT3 was expressed and purified fresh, and a reference spectrum was acquired. Then, the complex of STAT3 with each of the compounds was collected as described before. Sequences of qPCR primers for the TET1 promoter sites are: Site 1 forward: 5′-ACCTTGTGACCTTCAAAGTGCTGGA-3′; reverse: 5′-ACCTGGTAGTGCTGACTTCCCT-3′; Site 2 forward: 5′-TTTGGGAAACGCTICTCACTCCT-3′; reverse: 5′-TCGGGGAAACGTCTCTACTGGC-3′; Site 3 forward: 5′-AGGCTGGTTGGTTGATCCTCACTA-3′; reverse: 5′-TATTGGTG-CAAGCCTTGTATTGCCTG-3′; Site 4 forward: 5′-CCATTCCCGGACCAGACCA-3′; reverse: 5′-TTGCGGATCTGAGCTTGGAGA-3′.

Electrophoretic-mobility shift assay. EMSA was conducted with EMSA Assay Kit (Signosis, Santa Clara, CA) according to the manufacturer’s instructions with minor modifications. Briefly, purified STAT3 protein was incubated with Biotin-labeled TET1-CPG probe (hot probe) and/or cold probe, and then protein/DNA complexes were collected on a non-denaturing polyacrylamide gel. Bands were detected using Streptavidin-HRP conjugate and a chemiluminescent substrate. The sequences of the TET1-CPG probe are: Forward: 5′-Biotin- CGGTTAGGCGTCTCCGCGACGGC-3′; Reverse: 5′-Biotin-GCTGGTTGGTGGTTGATCCTCACTA-3′.

Western blotting. Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and ruptured with RIPA buffer (Pierce, Rockford, IL) containing 5 mM EDTA, PMSF, cocktail inhibitor, and phosphatase inhibitor cocktail. Cell extracts were microcentrifuged for 20 min at 10,000 × g and supernatants were collected. Cell lysates were resolved by SDS-PAGE and transferred onto PVDF membranes. For each sample, 50 μg of protein was loaded on each membrane. Membranes were blocked for 1 h with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20 and incubated overnight at 4 °C with anti-Tet 1 (1:1000) (GTI1462, GeneTex, Irvine, CA), anti-STAT3 (1:1000) (C-20, Santa Cruz Biotechnology, Dallas, TX), anti-STAT3 (phospho-Y705) (1:1000) (ab76315, Abcam, Cambridge, UK), anti-STAT3 (1:1000) (610191, BD Biosciences, San Jose, CA), or anti-STAT3 (1:1000) (9035T, Cell Signaling Technology Inc., Danvers, MA), anti-JAK1 (1:1000) (ab133666, Abcam), anti-JAK2 (phospho-Y1022/Y1023) (1:1000) (ab138005, Abcam), anti-GAPDH (1:1000) (8H10D10, Cell Signaling Technology Inc.). Membranes were washed 30 min with Tris-buffered saline containing 0.1% Tween 20, incubated for 1 h with appropriate secondary antibodies conjugated to horseradish peroxidase, and developed using chemiluminescence substrates.

ShmC labeling reaction and dot blotting. The 5-hydroxyethylcytosine (5hmC) labeling reactions and ShmC dot blotting were performed as described previously41,46. Briefly, 3 μg sonicated genomic DNA (100–500 bp) fragments were incubated in solution containing 50 mM HEPES buffer (pH 7.9), 25 mM MgCl2, 100 μM UDP-6-N3-Glc, and 1 μM beta-glucosyltransferase (β-GT) for 1 h at 37 °C. The CLICK was performed with addition of 150 μM dibenzocyclooctyne modified biotin into the purified DNA solution, and the reaction mixture was incubated for 2 h at 37 °C. Six hundred nanograms of labeled genomic DNA samples were spotted on a nylon membrane (Gene Satellite, LG Healthcare, Little Chalfont, UK). DNA was fixed to the membrane by Stratagene UV Stratalinker 2400 (auto-crosslink). The membrane was then blocked with 5% BSA and incubated with Avidin-HRP (1:40,000) (Bio-Rad, Hercules, CA), and then visualized by enhanced chemiluminescence.

Cell line construction. Hundred nanograms of genomic DNA extracted from ML-2 cell were fragmented in 50 μL Tagmentation buffer at 35 °C. Fragmented DNA was purified by Zymo DNA clean&concentrator Kit (Zymo Research, Tustin, CA). Then, the selective ShmC chemical labeling was performed in 25 μL glucosylation buffer (50 mM HEPES buffer pH 8.0, 25 mM MgCl2) containing above fragmented DNA, 100 μM N2-UDP-Glc, 1 μM β-GT, and incubated at 37 °C for 2 h. After purified in 45 μL ddH2O, 1.5 μL DBCO-PEG4-Biotin (Click Chemistry Tools, 4.5 mg/mL stored in DMSO) was added and incubated at 37 °C for 2 h. The biotin labeled DNA was pulled down by 5 μL C1 Streptavidin beads (Life Technologies, Carlsbad, CA) for 15 min at room temperature. Next, the captured DNA fragments were subjected to 13 cycles of PCR amplification using Nextera DNA sample preparation kit (Illumina, San Diego, CA). The resulting amplified product was purified by 1.0× AMPure XP beads. Input library was made by direct PCR from fragmented DNA without chemical labeling and capture. The libraries were quantified by a Qubit fluorometer (Life Technologies) and sequenced on an Illumina HiSEQ4000 sequencer with paired-end 50-bp reads.

Mutation calling from RNA-Seq. THP-1 cells were grown in RPMI1640 medium containing 10% FBS and treated with 250 μM 4-MU 5-NCST-370284 for 120 days. RNA was extracted using Qiagen miRNeasy kit. Library was prepared by PrepX mRNA Library Kit (WaferGen) combined Apollo 324 NGS automated library prep system. Libraries at the final concentration of 15 pM were clustered onto a single read (SR) flow cell using Illumina TruSeq SR Cluster kit v3 and sequenced to 50 bp paired-end 100 cycles using Illumina GAIIx platform. Reads were aligned to the hg19 genome assembly using STAR with default parameters. GATK was used to call the mutations from mapped RNA-Seq reads. ANNOVAR was used to annotate
the mutations. The raw data were deposited to NCBI SRA under the accession number SRP103997.

Statistical software and statistical analyses. The gene network was analyzed with Ingenuity Pathway Analysis (Qiagen). The modeling of protein–DNA/chemical compound binding was conducted with Molsoft ICM-Pro (Molsoft LLC., San Diego, CA). The t-test, Kaplan–Meier method, log-rank test, etc. were performed with WinSTAT (R. Fitch Software), GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA), and/or Partek Genomics Suite (Partek Inc.). The P values less than 0.05 were considered as statistically significant. For 5hmC sequencing analysis, illumina sequencing reads were mapped to UCSC hg19 human reference genome using bowtie program41. Only uniquely mapped reads sequencing analysis, illumina sequencing reads were mapped to UCSC hg19 human reference genome using bowtie program41. Only uniquely mapped reads were retained for the following data analysis. PCR duplicates were removed using samtools62. The identification of 5hmC peaks in each sample was performed using MACS83 and an IDR cutoff of 0.01 was used to filter high confident peaks84. Peaks from different samples were merged together into a unified catalog of 5hmC enriched regions using HOMER85. To visualize sequencing signals in IGV86, BigWig files were generated by deepTools with RPKM normalization method. All the data meet the assumptions of the tests, with acceptable variation within each group, and similar variance between groups.

Data availability. Data referenced in this study are available in The Gene Expression Omnibus. The 5hmC sequencing data is available under GSE97407 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=etodaoikjtwnpgb&acc=GSE97407). RNA-Seq data is available under SRP103997 and GSE101480.

Received: 6 May 2017 Accepted: 17 November 2017 Published online: 13 December 2017

References

1. Marcucci, G., Mrozek, K. & Bloomfield, C. D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr. Opin. Hematol. 12, 68–75 (2005).

2. Rowley, J. D. Chromosomal translocations: revisited yet again. Blood 112, 2183–2199 (2008).

3. Chen, J., Odenike, O. & Rowley, J. D. Leukaemogenesis: more than mutant genes. Nat. Rev. Genet. 10, 23–36 (2010).

4. Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136–1152 (2015).

5. Dohner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453–474 (2010).

6. Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325–4336 (2002).

7. Grimwade, D. & Mrozek, K. Diagnostic and prognostic value of cytogenetics in cytogenetics. Proc. Natl Acad. Sci. USA 110, 11994–11999 (2013).

8. Zhao, Z. et al. Combined loss of Tel1 and Tet2 promotes B cell, but not myeloid malignancies, in mice. Cell Rep. 13, 1692–1704 (2015).

9. D Malketty, M. M. et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 9, 166–175 (2011).

10. Shoemaker, R. H. The NCI60 human cell line cancer anticancer drug screen. Nat. Rev. Cancer 6, 813–823 (2006).

11. Yan, M. et al. A previously unidentified alternatively spliced isoform of t(8;21) translocation promotes leukemogenesis. Nat. Med. 12, 945–949 (2006).

12. Ratka, J. K., Kang, G. J., Jurd, L. & Hamel, E. Methylatedenoxynbenzoapran analogs of podophyllotoxin, a new synthetic class of antiangiogenic agents that inhibit tubulin polymerization. Biochem. Pharmacol. 37, 2595–2602 (1988).

13. Goraislov, M. A. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 44, 441–459 (2004).

14. Wacker, S. A., Houghtaling, B. R., Elemento, O. & Kapoor, T. M. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat. Chem. Biol. 8, 235–237 (2012).

15. Tseng-Rogenski, S. S., Hamaya, Y., Choi, D. Y. & Carethers, J. M. interferon-6 alters localization of hmsF2, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology 148, 579–589 (2015).

16. Okumura, F., Okumura, A. J., Matsumoto, M., Nakayama, K. I. & Hatakeyama, S. TRIM48 regulates Nanog via Hsp90beta-mediated nuclear translocation of STAT3 in embryonic stem cells. Biochem. Biophys. Acta 1813, 1784–1792 (2011).

17. Cheng, M. B. et al. Stat1 mediates a auto-regulation of hsp90beta gene in heat shock response. Cell. Signal. 22, 1206–1213 (2010).

18. Gagarin, D. et al. Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. J. Mol. Cell. Cardiol. 39, 453–465 (2005).

19. Huang, Y. et al. Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle 7, 1613–1622 (2008).

20. Kim, R. K. et al. Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer. Oncotarget 7, 53430–53442 (2016).

21. Shien, K. et al. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol. Cancer Ther. 16, 2234–2245 (2017).

22. Dae, S., Chatterjee, R., Law, A. & Law, S. Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome. Chem. Biol. Interact. 260, 176–185 (2016).

23. Su, R. et al. microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. Oncogene 35, 6001–6014 (2016).

24. Namanja, A. T., Wang, J., Buettner, R., Colson, L. & Chen, Y. Allosteric communication across STAT3 domains associated with STAT3 function and disease-causing mutation. J. Mol. Biol. 428, 579–589 (2016).

25. Buettner, R. et al. Alkylation of cysteine 468 in Stat3 depletes alternatively spliced isoform of t(8;21) translocation promoting leukemogenesis. Cancer Cell 29, 453–465 (2010).

26. Fatrai, S., Wierenga, A. T., Daenen, S. M., Vellenga, E. & Schuringa, J. J. Identification of HIF2alpha as an important STAT3 target gene in human hematopoietic stem cells. Blood 117, 3320–3330 (2011).

27. Nagy, Z. S. et al. Genome wide mapping reveals PDE4B as an IL-2 induced STAT5 target gene in activated human PBMCs and lymphoid cancer cells. PLoS ONE 8, e57326 (2013).

28. Rani, A., Greenlaw, R., Runglall, M., Jurcovic, S. & John, S. FRA2 is a STAT5 gene targeted by IL-2 in human CD4 T cells. PLoS ONE 9, e93070 (2014).

29. Nelson, E. A., Walker, S. R., Alvarez, J. V. & Frank, D. A. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J. Biol. Chem. 279, 45724–45730 (2004).

30. Hart, S. et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 1, e44 (2011).

31. Pratz, K. W. et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 113, 3938–3946 (2009).

32. Schutt, J., Sperl, R., Hollis, A., Mayer, T. U. & Berg, T. Stat5: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13, 1235–1242 (2006).

33. Ruppert, S. M., Falk, B. A., Long, S. A. & Bollinky, P. L. Regulatory T cells resist cyclosporine-induced cell death via CD44-mediated signaling pathways. Int. J. Cancer 125, 614297 (2015).

34. Li, X. et al. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat. Commun. 7, 11452 (2016).
47. Sun, M. et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl Acad. Sci. USA 110, 9920–9925 (2013).
48. Zuber, J. et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23, 877–889 (2009).
49. Varmeh, S. & Manfredi, J. J. Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death. Mol. Cancer Ther. 7, 3789–3799 (2008).
50. Barry, S. P. et al. STAT3 modulates the DNA damage response pathway. Int. J. Exp. Pathol. 91, 506–514 (2010).
51. Zheng, Y. et al. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 118, 156–166 (2011).
52. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–526 (2011).
53. Chu, S. H. & Small, D. Mechanisms of resistance to FLT3 inhibitors. Drug Resist. Updates 12, 8–16 (2009).
54. Grunwald, M. R. & Levis, M. J. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int. J. Hematol. 97, 683–694 (2013).
55. Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538–542 (2015).
56. Jiang, X. et al. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res. 76, 4470–4480 (2016).
57. Jiang, X. et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 22, 524–535 (2012).
58. Zhang, Y., Huo, M., Zhou, J. & Xie, S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput. Methods Prog. Biomed. 99, 306–314 (2010).
59. Li, Z. et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumor suppressor in MLL-rarranged leukaemia. Nat. Commun. 2, 688 (2012).
60. Jiang, X. et al. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rarranged leukemia. Proc. Natl Acad. Sci. USA 109, 19397–19402 (2012).
61. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
62. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
63. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
64. Landt, S. G. et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 22, 1813–1831 (2012).
65. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).
66. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
67. Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187–191 (2014).

Acknowledgements
The authors are grateful to Drs Junlin Guan, Saijuan Chen and Raibao Ren for their constructive comments. We also thank Dr Xiang Zhang (supported by University of Cincinnati College of Medicine Core Enhancement Funding 2017) for the RNA seq assays. This work was supported in part by the National Institutes of Health (NIH) R01 Grants CA211614 (J.C.), CA178454 (J.C.), CA214965 (J.C.), CA182528 (J.C.), RMI HG008935 (C.H.), Gabrielle’s Angel Foundation for Cancer Research (X.J.), The University of Chicago Committee on Cancer Biology (CCB) Fellowship Program (X.J.), National Natural Science Foundation of China (91125305) (C.H.), Foundation of Innovation Team for Basic and Clinical Research of Zhejiang Province (2011R50015) (J.C.), LLS Scholar. C.H. is an investigator of the Howard Hughes Medical Institute (HHMI). WCR and PPL are supported by intramural research programs of NCI and NIH, respectively.

Author contributions
X.J. and J.C. conceived the project and designed the research. X.J., C.H., K.F., J.N., X.C., C.-H.C., L.C., Z.Z., C.H., Y.T., W.S., J.R.S., M.W., W.C.R., I.D., C.S., S.A., B.U., J.L., H.W., R.S., H.H., Y.W., C.L., X.Q., J.M., Y.Z., J.D., J.L., C.L., P.P.L., C.H., Y.C. and J.C. performed experiments and/or data analysis. X.J., X.C., Z.Z., J.M., Y.Z., J.D., C.L., W.S., C.H., Y.C. and J.C. contributed reagents/analytic tools and/or grant supports. X.J. and J.C. wrote the paper. All authors discussed the results and commented on the manuscript.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-017-02290-w.

Competing interests: A patent (to X.J. and J.C.) was applied for based on this work. C.H. is a scientific founder of the Accent Therapeutics, Inc. The remaining authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2017